New drug trial aims to tame debilitating nosebleeds in rare disorder
NCT ID NCT06659640
Summary
This study is testing a new drug called ALN-6400 to see if it is safe and can help control bleeding in adults with hereditary hemorrhagic telangiectasia (HHT), a disorder that causes frequent, severe nosebleeds. The first part tests single doses in healthy volunteers, and the second part tests multiple doses in people with HHT to measure its effect on bleeding frequency and severity. The main goals are to check for side effects and see if the drug reduces the need for blood transfusions and improves quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY HEMORRHAGIC TELANGIECTASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Trial Site
RECRUITINGCypress, California, 90630, United States
-
Clinical Trial Site
RECRUITINGBoston, Massachusetts, 02114, United States
-
Clinical Trial Site
RECRUITINGMount Royal, H3P 3P1, Canada
-
Clinical Trial Site
RECRUITINGToronto, M5B 1W8, Canada
-
Clinical Trial Site
RECRUITINGBordeaux, 33000, France
-
Clinical Trial Site
RECRUITINGBron, 69500, France
-
Clinical Trial Site
RECRUITINGHomburg, 66421, Germany
-
Clinical Trial Site
RECRUITINGL'Hospitalet de Llobregat, 8907, Spain
Conditions
Explore the condition pages connected to this study.